(Q39625075)

13 September 2017

1 reference

title

The action of antitumor agents: a double-edged sword? (English)

1 reference

13 September 2017

The action of antitumor agents: A double-edged sword? (English)

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

21 March 2023

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

21 March 2023

author name string

S. M. Sieber

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A327250

21 March 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=327250

21 March 2023

publication date

1 January 1977

1 reference

full work available at URL

13 September 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fmpo.2950030203

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

https://onlinelibrary.wiley.com/doi/full/10.1002/mpo.2950030203

21 March 2023

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

21 March 2023

published in

Pediatric Blood Cancer

1 reference

Medical and Pediatric Oncology

13 September 2017

3

2

123–31

1977

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=327250

21 March 2023

volume

3

1 reference

13 September 2017

2

1 reference

13 September 2017

123-131

1 reference

Trophoblastic disease: natural history, diagnosis, and treatment

13 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FMPO.2950030203

Melphalan and myeloma. Experience with a low-dose continuous regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMPO.2950030203

Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer

21 January 2018

8

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

Hodgkin's disease terminating in acute leukemia.

21 March 2023

9

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

Myeloid leukemia in Hodgkin's disease: chromosomal abnormalities

21 March 2023

10

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

Chronic myelogenous leukemia in Hodgkin's disease: Immunofluorescence of cells

21 March 2023

11

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

Myelomonocytic leukemia in Hodgkin's disease

21 March 2023

13

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

Acute granulocytic leukemia complicating Hodgkin's disease

21 March 2023

15

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

LEUKEMIA AND HODGKIN'S DISEASE

21 March 2023

16

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

Acute leukemia in Hodgkin's disease.

21 March 2023

17

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

Recently recognized complications of cancer chemotherapy

21 March 2023

19

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

Secondary neoplasms in malignant lymphomas after intensive therapy

21 March 2023

20

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

Multiple myeloma and acute myelomonocytic leukemia

21 March 2023

21

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

21 March 2023

Leukaemia on myeloma

23

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

Alkylating agents as leukemogens in multiple myeloma

21 March 2023

24

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

Monocytic and monomyelocytic leukaemia with increased serum and urine lysozyme as a late complication in plasma cell myeloma

21 March 2023

25

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

Stem cell leukaemia in myelomatosis

21 March 2023

26

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

21 March 2023

Leukaemia on myeloma

27

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

21 March 2023

Leukemia on myeloma

29

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

Unusual cases of myelomatosis.

21 March 2023

30

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

21 March 2023

Epidemic acute leukemia

31

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

Myelomonocytic leukaemia supervening on chronic lymphocytic leukaemia

21 March 2023

33

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

Letter: Androgen role in erythroleukemia after treatment with alkylating agents

21 March 2023

36

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

Acute leukemia complicating metastatic breast cancer

21 March 2023

37

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

Acute myeloid leukaemia after treatment with cytostatic agents

21 March 2023

38

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

Acute myeloid leukaemia after treatment with cytostatic agents

21 March 2023

39

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

Acute erythromegakaryocytic leukaemia after treatment with cytostatic agents

21 March 2023

42

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

Second malignancies complicating Hodgkin's disease in remission

21 March 2023

46

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

Carcinoma coexistent with malignant disorders of plasma cells; an autopsy survey

21 March 2023

48

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

Extraosseous lesions in plasma cell myeloma. A report of six cases

21 March 2023

50

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

The Carcinogenic Properties of Some of the Principal Drugs Used in Clinical Cancer Chemotherapy

21 March 2023

55

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

21 March 2023

58

30

2271

Svoboda

1970

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

Different incidence of breast carcinomas or fibroadenomas in daunomycin or adriamycin treated rats

21 March 2023

59

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

Immune reactivity prior to development of thymic lymphoma in C57BL mice

21 March 2023

61

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

Previous and simultaneous cancers in patients with leukemia

21 March 2023

65

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

21 March 2023

66

4

554

Warren

1944

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

Hodgkin's disease and acute leukemia. Report of eight cases and review of the literature

21 March 2023

67

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

Reticulosis as a Long-Term Side-Effect of Methotrexate Therapy in a Patient with Generalized Psoriasis and Psoriatic Arthritis

21 March 2023

68

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

Development of malignant cerebral lymphoma in a patient with systemic lupus erythematosus treated with immunosuppression

21 March 2023

72

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

Nephrotic Syndrome Due to Primary Renal Disease in Adults: II. A Controlled Trial of Prednisolone and Azathioprine

21 March 2023

73

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

Immunosuppression and malignancy.

21 March 2023

74

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

Chemical immunosuppression and human cancer

21 March 2023

75

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

Risk of cancer in renal-transplant recipients.

21 March 2023

76

1 reference

https://api.crossref.org/works/10.1002/MPO.2950030203

21 March 2023

Identifiers

1 reference

13 September 2017

1 reference